Navigation Links
Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal

tion therefore would have a significant positive impact on patients undergoing CABG surgery. Given the limited success of prophylactic drug therapy for atrial fibrillation, the beneficial effects of MC-1 are promising and warrant further evaluation in future studies."

About MEND-CABG

The MEND-CABG trial, completed in 2006, was a Phase 2 study involving 901 patients that evaluated MC-1 versus placebo in individuals undergoing CABG surgery at 42 investigational sites throughout Canada and the United States.

The 250 mg dose of MC-1 had a 37.2% reduction in the composite of cardiovascular death, non-fatal myocardial infarction (peak CK-MB ?100ng/ml), and non-fatal stroke versus placebo (p@028).

The reduction in the composite endpoint was driven by a significant 46.9% decrease in the incidence of non-fatal myocardial infarction (peak CK-MB ?100ng/ml) with the 250 mg dose of MC-1 versus placebo (p@008).

The clinical results reported at POD 30 were maintained throughout the 90 day follow-up period (POD 90). Safety analysis included in the MEND-CABG study demonstrated that MC-1 was well tolerated. No safety concerns were identified; the incidence of adverse events in the study was comparable across both treatment and control groups.

The MEND-CABG trial was the catalyst to Medicure's ongoing Phase 3 MEND-CABG II study.

About MEND-CABG II

The Phase 3 MEND-CABG II is a double-blind, randomized, placebo-controlled clinical trial that will enroll up to 3,000 patients undergoing CABG surgery at approximately 120 cardiac surgical centers throughout North America and Europe. Study patients will be randomized to receive placebo or MC-1 250 mg prior to surgery and for 30 days post operatively (POD 30). The primary efficacy endpoint of MEND-CABG II is the reduction in the composite of cardiovascular death and non-fatal myocardial infarction up to POD 30. Study patients will be followed for 60 days after treatment (90 days post op
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Medicure MEND CABG Trial Results Published Peer Reviewed Journal
(Date:9/23/2014)... SAN DIEGO , Sept. 23, 2014  While proton therapy recently ... brain cancer patent Ashya King , another case in ... promising outlook, as a young boy who was given just days to ... When 5-year-old Logan Green of Arizona ... a dizzying journey of medical treatments that will conclude Sept. 23, when ...
(Date:9/23/2014)... , September 23, 2014 ... oncology biopharmaceutical company, today announces it has been ... Drug Discovery Award from the UK,s Wellcome Trust ... its proprietary, novel cancer target. The ... identify and fund especially promising, innovative new therapeutic ...
(Date:9/23/2014)... EVANSTON, Ill. , Sept. 23, 2014 /PRNewswire/ ... more look to digital communication channels to learn ... companies. This finding – from a new report ... ZS – shows that communicating via a ... sales representatives provides the best opportunity to engage ...
Breaking Medicine Technology:5-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 25-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 4BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5
... Use of,a low profile PressureWire yields a ... to catheter-derived pressure gradient,(CPG) measurements, according to a ... Vol. 20, Issue 1: 63-65)., The authors ... a,catheter and PressureWire correlated with anatomic stenosis, PressureWire,gradient ...
... 27 Puroast(R) Low Acid Coffee,has conducted both ... its great tasting, gourmet coffee provides symptom relief ... brew. Puroast(R) achieves,this without extractions, substitutes or additives; ... full-bodied taste., Prior chemistry research at University ...
Cached Medicine Technology:Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 2Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 3Low Acid Coffee Backed By Scientific Research 2
(Date:9/23/2014)... Karen Pallarito HealthDay Reporter ... if doctors and hospitals got paid for providing better ... better data for making informed health choices. A ... is headed. The report, from the IMS Institute for ... -- recent events expected to alter the delivery of health ...
(Date:9/23/2014)... Avid collector Andrew Hawley, from Vintage Rock ... Auditorium Seattle concert posters. The Doors were a smash hit ... year. The Seattle Eagles Auditorium concert was held on July ... to Eagles Auditorium in November the same year. The artist ... comes in three colors. The poster is a split fountain ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- Few children ... undergo behavioral therapy, and the rates vary six-fold ... study finds. Medication alone can manage symptoms ... better if they also receive behavioral therapy (psychotherapy), ... analyzed data in more than 1,500 counties across ...
(Date:9/23/2014)... the benefits of preventing a reduction in the ... released today by the American College of Physicians ... the Medicaid Primary Care Pay Parity Program: Unless ... Primary Care Will Expire," explains why it is ... and pediatricians (and their related subspecialists), family physicians, ...
(Date:9/23/2014)... 23, 2014 The global ... (AR) is highly fragmented, with the US, ... available, under different regulatory restrictions, with almost ... has the most developed market, with subcutaneous ... immunotherapy tablets (AITs) all being available. However, ...
Breaking Medicine News(10 mins):Health News:Report Identifies Game Changers for U.S. Health Care 2Health News:Report Identifies Game Changers for U.S. Health Care 3Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4
... rehabilitation professionals expect 20-plus percent employment increases through 2016. ... ... September 8, 2008 -- People reach significant milestones through ... the http://www.nraf-rehabnet.org/ [National Rehabilitation Awareness Foundation], which ...
... Common painkillers like aspirin and ibuprofen appear to lower a ... to help gauge whether a man is at risk of ... appears online Sept. 8 in the journal Cancer , ... to prevent prostate cancer just yet. , "We showed ...
... Pa., Sept. 5 Lieutenant Governor,Catherine Baker Knoll today ... Blood Donor Day., The Commonwealth of Pennsylvania and ... to give blood in commemoration of those who lost ... supplies. One blood,donation can save up to three lives., ...
... John McCain to commit to develop a National AIDS,Strategy ... Sep. 5 The,Republican National Convention concluded last night ... United States and only passing reference to,the epidemic overseas. ... Gov. Sarah Palin mentioned AIDS in their remarks,to Convention ...
... 5 On Saturday, September 6, PARI,Respiratory Equipment will ... part of their "Breathe Easier" series. PARI is highlighted ... as COPD,sufferers, with effective nebulizers and compressors that deliver ... to improve the lives of those affected by respiratory,diseases ...
... disease resistance to anti-hormonal therapy , , FRIDAY, Sept. ... help "re-sensitize" certain breast cancer tumors to anti-hormonal ... , Women with estrogen-receptor or progesterone-receptor positive (ER ... anti-hormonal medicines, such as aromatase inhibitors, to keep ...
Cached Medicine News:Health News:U.S. Demand for Rehabilitation Professionals Grows 2Health News:U.S. Demand for Rehabilitation Professionals Grows 3Health News:Common painkillers lower levels of prostate cancer biomarker 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3Health News:PARI Respiratory Equipment Featured on Oxygen Network 2Health News:Drug Re-Sensitizes Breast Tumors to Treatment 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: